Literature DB >> 31738141

Risk of Kidney Dysfunction IN Nafld.

Alessandro Mantovani1, Chiara Zusi1, Andrea Dalbeni2, Giorgio Grani3, Elena Buzzetti4.   

Abstract

BACKGROUND: The timely identification of traditional and non-traditional precursors and risk factors for chronic kidney disease (CKD) (a common systemic disease defined as a decreased kidney function documented by reduced glomerular filtration rate, or markers of kidney damage, or both) is relevant in clinical practice, as CKD increases the risk of end-stage renal disease and other serious comorbidities. A possible relationship between non-alcoholic fatty liver disease (NAFLD) (which is to date the most common chronic disease worldwide) and CKD has recently gained significant attention of researchers.
METHODS: A systematic literature search using appropriate keywords was made in order to identify relevant articles that have investigated the association between NAFLD and CKD.
RESULTS: Several observational studies and meta-analyses have reported the existence of an independent association between NAFLD and risk of CKD in patients with and without diabetes. However, whilst the association between NAFLD and risk of prevalent CKD is strong across various patient populations, whether NAFLD is independently associated with the development and progression of CKD is still debatable. Moreover, emerging evidence now suggests a potential association between patatin-like phospholipase domain-containing protein-3 (PNPLA3) rs738409 genotype (the most important genetic variant associated to NAFLD) and decreasing kidney function, independent of NAFLD.
CONCLUSION: Convincing evidence now indicates that CKD is increased among patients with NAFLD. For this reason, patients with NAFLD should be regularly monitored for renal function and, on the other hand , NAFLD should be considered in all patients with CKD, especially if they are obese or have type 2 diabetes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CKD; NAFLD; Non-alcoholic fatty liver disease; chronic kidney disease; phospholipase; renal dysfunction.

Year:  2020        PMID: 31738141     DOI: 10.2174/1381612825666191026113119

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  MAFLD and CKD: An Updated Narrative Review.

Authors:  Alessandro Mantovani; Rosa Lombardi; Filippo Cattazzo; Chiara Zusi; Davide Cappelli; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 2.  Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review.

Authors:  Luca Rinaldi; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Maria Vittoria Morone; Chiara Silvestri; Mauro Giordano; Teresa Salvatore; Ferdinando Carlo Sasso
Journal:  Antioxidants (Basel)       Date:  2021-02-10

Review 3.  Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes.

Authors:  Alessandro Mantovani; Andrea Dalbeni; Giorgia Beatrice; Davide Cappelli; Fernando Gomez-Peralta
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

4.  Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.

Authors:  Sahar Samimi; Sahar Rajabzadeh; Soghra Rabizadeh; Manouchehr Nakhjavani; Pooria Nakhaei; Foroogh Alborzi Avanaki; Alireza Esteghamati
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

5.  Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation.

Authors:  Zijin Xu; Susu Lin; Junjie Gong; Peishi Feng; Yifeng Cao; Qiaoqiao Li; Yuli Jiang; Ya You; Yingpeng Tong; Ping Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.